Edgar Filing: Kauffman Michael - Form 4

Kauffman M Form 4	lichael									
November 2										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									OMB APPROVAL	
Check th	Wa	shington,	D.C. 20	549			Number:	3235-0287 January 31,		
if no lon; subject to Section 1 Form 4 c Form 5	6. Filed pursu	ENT OF CHAN	SECUR	RITIES				Expires: Estimated a burden hou response	2005 average urs per	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type]	Responses)									
1. Name and Address of Reporting Person _2. IssueKauffman MichaelSymbol			er Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer			
	pharm Therapeutics Inc.]				(Check all applicable)					
(Last)	f Earliest Transaction Day/Year)				_X_ Director 10% Owner _X_ Officer (give title Other (specify					
C/O KARY THERAPE AVENUE	OPHARM UTICS INC., 85 W	11/26/2	-				below) Chief E	below) Executive Offic	er	
	endment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
NEWTON, MA 02459				Form filed by I Person				lore than One Re	eporting	
(City)	(State) (Z	Zip) Tab	le I - Non-E	Derivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				Beneficially Owned Following Reported Transaction(s)	OwnershipInForm: DirectB(D) orC			
Common				Amount		Price \$	(Instr. 3 and 4)			
Stock	11/26/2018		M <u>(1)</u>	9,600	А	ф 4.752	521,743	D		
Common Stock	11/26/2018		S <u>(1)</u>	9,600	D	\$11	512,143	D		
Common Stock							713,510	Ι	By Spouse	
Common Stock							47,309	I	By GRAT	
							47,309	Ι		

Edgar Filing: Kauffman Michael - Form 4

Common
Stock

By Spouse's GRAT (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration E (Month/Day	Date	Underlying Securities I (Instr. 3 and 4)		8. l De Sec (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 4.752	11/26/2018		M <u>(1)</u>	9,600	(4)	09/02/2023	Common Stock	9,600	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Kauffman Michael C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE NEWTON, MA 02459	х		Chief Executive Officer				
Signatures							
/s/ Christopher B. Primiano, Attorney-in-Fact fo Kauffman	r Michael	G.	11/27/2018				
**0' ())			Dete				

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- (2) These shares are held by the Michael G. Kauffman 2016 Qualified Annuity Interest Trust.
- (3) These shares are held by the Sharon Shacham 2016 Qualified Annuity Interest Trust.
- (4) This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.